Author:
Devanand D. P.,Fremont R.
Publisher
Springer International Publishing
Reference309 articles.
1. Adair, J. C., Knoefel, J. E., & Morgan, N. (2001). Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology, 57(8), 1515–1517.
2. Adem, A., Mohammed, A. K., & Winblad, B. (1990). Multiple effects of tetrahydroaminoacridine on the cholinergic system: Biochemical and behavioural aspects. Journal of Neural Transmission Parkinsons Disease and Dementia Section, 2, 113–128.
3. Aisen, P. S., & Davis, K. L. (1994). Inflammatory mechanisms in Alzheimer’s disease: Implications for therapy. American Journal of Psychiatry, 151, 1105–1113.
4. Aisen, P. S., Davis, K. L., Berg, J. D., et al. (2000). A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology, 54, 588–593.
5. Aisen, P. S., Schafer, K., Grundman, M., et al. (2002). Results of a multicenter trial of rofecoxib and naproxen in Alzheimer’s disease. Neurobiology of Aging, 23, S429.